Advanced search
Start date
Betweenand

Renal cancer genetic susceptibility

Grant number:20/10960-5
Support Opportunities:Research Grants - Young Investigators Grants
Start date: August 01, 2021
End date: July 31, 2026
Field of knowledge:Health Sciences - Medicine - Medical Clinics
Principal Investigator:Leandro Machado Colli
Grantee:Leandro Machado Colli
Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
City of the host institution:Ribeirão Preto
Associated researchers:Aline Gomes de Souza ; David Mole ; Dirce Maria Carraro ; Eliezer M. Van Allen ; Fernanda Maris Peria ; Katiuchia Uzzun Sales ; Maria Aparecida Azevedo Koike Folgueira ; Mark Purdue ; Peter Jonh Ratcliffe ; Ricardo Zorzetto Nicoliello Vêncio ; Rodolfo Borges dos Reis ; Stephen Chanock
Associated research grant(s):25/14030-6 - Future Scientists: impact of germline variation on toxicity and response to cancer treatment., AP.R
23/01274-9 - Proteogenomic evaluation of patients with Kidney Cancer treated with immunotherapy, AP.R
21/10880-4 - Multi-user equipment approved in grant 2020/10960-5: xCELLigence RTCA DP, AP.EMU
Associated scholarship(s):23/12702-1 - Correlation between clonal mosaicism and HR+/HER2- breast cancer, BP.IC
22/12980-9 - Post-GWAS study for the 2q22 risk region for renal cancer, BP.PD
22/14894-2 - PROTEOGENOMIC EVALUATION OF PATIENTS WITH KIDNEY CANCER TREATED WITH IMMUNOTHERAPY, BP.PD
21/14853-1 - DPF3 Impact on Renal Cancer: from susceptibility to murine treatment with immunotherapy, BP.DD
21/13304-4 - IDO1 inhibitor and anti IL-23 as a therapy for in vitro renal cell Carcinoma, BP.IC

Abstract

Genome-wide association studies (GWAS) are an important tool for the characterization of the genetic architecture of cancer susceptibility, and a key step towards understanding the process of cancer development. Each susceptibility region explains only a small fraction of cancer risk, but the aggregation of those regions allows us to understand a significant part of the heritability, using polygenic risk scores. Renal cancer GWAS have detected 13 susceptibility regions, which explains 14% of the germline risk. Precision prevention will use polygenic risk scores to individualize strategies for screening and primary prevention. However, it is necessary to increase our knowledge of renal cancer susceptibility in order to create a meaningful polygenic risk score for this tumor. This proposal comprises three main complementary research plans. Therefore, for our first research plan, we will use a new GWAS with Brazilian samples to identify additional renal cancer susceptibility regions, as well as develop new strategies to transpose polygenic risk scores into different populations. Since risk regions are unique agnostic opportunities to identify new molecular oncogenic mechanisms, for research plan 2 a post-GWAS study will evaluate the deregulation of key tumor-specific pathways by risk variants. During his postdoc at NIH, the Principal Investigator developed a series of large-scale screening functional assays (ATAC-seq, Chip-seq, eQTL, Capture-HiC, and MPRA) to prioritize top functional variants in each renal cancer susceptibility region. Here, we will use a functional follow-up study to identify the molecular mechanism for renal cancer development in three regions: 12p12, 14q24, and 2q22. Finally, for research plan 3, we will use the modern approach of germline and somatic interaction to evaluate the impact of germline susceptibility on renal cancer prognosis and treatment outcome. In summary, we think this proposal is a unique opportunity to develop a translational genotype-molecular-phenotype study to generate and understand germline susceptibility, molecular mechanisms, and precision treatment for renal cancer. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
More itemsLess items
Articles published in other media outlets ( ):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
SILVA, SAULO BRITO; WANDERLEY, CARLOS WAGNER S.; COLLI, LEANDRO MACHADO. mmune Checkpoint Inhibitors in Tumors Harboring Homologous Recombination Deficiency: Challenges in Attaining Efficac. FRONTIERS IN IMMUNOLOGY, v. 13, . (20/10960-5)